Antithrombotic therapy in patients undergoing transcatheter aortic valve implantation
Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Standard
Antithrombotic therapy in patients undergoing transcatheter aortic valve implantation. / Nijenhuis, Vincent Johan; Brouwer, Jorn; Søndergaard, Lars; Collet, Jean Philippe; Grove, Erik Lerkevang; Ten Berg, Jurrien Maria.
I: Heart, Bind 105, Nr. 10, 2019, s. 742-748.Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Antithrombotic therapy in patients undergoing transcatheter aortic valve implantation
AU - Nijenhuis, Vincent Johan
AU - Brouwer, Jorn
AU - Søndergaard, Lars
AU - Collet, Jean Philippe
AU - Grove, Erik Lerkevang
AU - Ten Berg, Jurrien Maria
PY - 2019
Y1 - 2019
N2 - This review provides a comprehensive overview of the available data on antithrombotic therapy after transcatheter aortic valve implantation (TAVI). In the absence of large randomised clinical trials, clinical practice is leaning towards evidence reported in other populations. Due to the greater risk of major bleeding associated with oral anticoagulation using a vitamin-K antagonist (VKA), antiplatelet therapy (APT) may be considered as the first-line treatment of patients undergoing TAVI. Overall, single rather than dual APT is preferred. However, dual APT should be considered in patients with a recent acute coronary syndrome (ie, within 6 months), complex coronary stenting, large aortic arch atheromas or previous non-cardioembolic stroke. Monotherapy with VKA should be considered if concomitant atrial fibrillation or any other indication for long-term oral anticoagulation is present. APT on top of VKA seems only reasonable in patients with recent acute coronary syndrome, extensive or recent coronary stenting or large aortic arch atheromas. A direct-acting oral anticoagulant may be considered if oral anticoagulation is indicated in the absence of contraindications. Initiation of VKA is indicated in clinical valve thrombosis, for example, with high transvalvular gradient, whereas the role of VKA in the case of subclinical leaflet thrombosis is currently uncertain.
AB - This review provides a comprehensive overview of the available data on antithrombotic therapy after transcatheter aortic valve implantation (TAVI). In the absence of large randomised clinical trials, clinical practice is leaning towards evidence reported in other populations. Due to the greater risk of major bleeding associated with oral anticoagulation using a vitamin-K antagonist (VKA), antiplatelet therapy (APT) may be considered as the first-line treatment of patients undergoing TAVI. Overall, single rather than dual APT is preferred. However, dual APT should be considered in patients with a recent acute coronary syndrome (ie, within 6 months), complex coronary stenting, large aortic arch atheromas or previous non-cardioembolic stroke. Monotherapy with VKA should be considered if concomitant atrial fibrillation or any other indication for long-term oral anticoagulation is present. APT on top of VKA seems only reasonable in patients with recent acute coronary syndrome, extensive or recent coronary stenting or large aortic arch atheromas. A direct-acting oral anticoagulant may be considered if oral anticoagulation is indicated in the absence of contraindications. Initiation of VKA is indicated in clinical valve thrombosis, for example, with high transvalvular gradient, whereas the role of VKA in the case of subclinical leaflet thrombosis is currently uncertain.
KW - anticoagulant drugs
KW - antithrombotic
KW - aortic bioprosthesis
KW - aspirin
KW - clopidogrel
KW - transcatheter aortic valve implantation (TAVI)
KW - transcatheter aortic valve replacement (TAVR)
U2 - 10.1136/heartjnl-2018-314313
DO - 10.1136/heartjnl-2018-314313
M3 - Review
C2 - 30867148
AN - SCOPUS:85062946203
VL - 105
SP - 742
EP - 748
JO - Heart
JF - Heart
SN - 1355-6037
IS - 10
ER -
ID: 240788571